实用肝脏病杂志2024，Vol.27Issue(1)：32-35,4.DOI:10.3969/j.issn.1672-5069.2024.01.009
三种DAAs方案治疗慢性丙型肝炎患者两年随访研究
Twenty-four month follow-up for patients with chronic hepatitis C after sustained virological response to different DAAs treatment regimen
摘要
Abstract
Objective The aim of this study was to investigate the twenty-four month follow-up efficacy for patients with chronic hepatitis C(CHC)after sustained virological response(SVR)to different direct-acting antiviral agents(DAAs)treatment regimen.Methods 123 patients with CHC were enrolled in our hospital between January 2018 and December 2020,and were divided into three groups,receiving sofosbuvir/velpatasvir(SOF/VEL)in 52 cases,elbasvir/grazoprevir(EBR/GZR)in 43 cases,and ledipasvir/sofosbuvir(LDV/SOF)in 28 cases.The antiviral regimen lasted for 12 weeks and all patients were followed-up for 24 weeks.Serum HCV RNA loads were detected by real-time fluorescence quantitative RT-PCR.The rapid virological response(RVR),early virological response(EVR),end of treatment virological response(ETVR)and SVR were recorded in three groups.Results The RVR in SOF/VEL-,EBR/GZR-and LDV/SOF-treated patients were 96.2%,93.0%and 92.9%,the EVR were 98.1%,97.7%and 96.4%,the ETVR and SVR in all patients were 100.0%,not significantly different among the three groups(all P>0.05);during the treatment,the incidences of untoward effects,such as nausea,fatigue and dizziness,in the three groups were 13.5%,11.6%and 21.4%,not significant different among them(P>0.05);7,7 and 5 patients with SVR in the three groups lost,all other patients with SVR were followed-up for 24 months,and no relapse or liver cancer were found.Conclusion All the antiviral regimen,with different DAAs have good efficacy as HCV GT1b infection is common in China,and no relatively long-term relapse.关键词
慢性丙型肝炎/直接抗病毒药物/持续病毒学应答/治疗Key words
Hepatitis C/Direct-acting antiviral agents/Sustained virological response/Therapy引用本文复制引用
王焱,韩军,杨美蓉..三种DAAs方案治疗慢性丙型肝炎患者两年随访研究[J].实用肝脏病杂志,2024,27(1):32-35,4.基金项目
中国肝炎防治研究基金会天晴肝病研究基金资助项目(编号:TQGB20210198) （编号:TQGB20210198）
